D-type cyclins are induced in response to mitogens and are essential and rate-limiting for G 1 phase progression in normal mammalian cells. Macrophages proliferating in response to colony-stimulating factor-1 (CSF-1) express cyclin D1 and to a lesser extent cyclin D2 but not cyclin D3. Previously we showed that the macrophageactivating agent lipopolysaccharide (LPS) blocks CSF-1-induced proliferation and cyclin D1 expression in macrophages. Here we report upon the effect of LPS on expression of cyclin D2 in normal mouse bone marrowderived macrophages (BMM). Unexpectedly we found that this anti-mitogen raised levels of CSF-1-stimulated cyclin D2 mRNA and protein. Cyclins are expressed during mitogenesis and control eukaryotic cell proliferation. D-type cyclins are induced by mitogens and are considered to be growth factor sensors (1). They are rate-limiting and essential for G 1 progression in normal mammalian cells since inhibition of either cyclin D1 (2, 3) or cyclin D2 (4) function will block G 1 progression in a number of cell types, whereas enforced expression of either cyclin can result in a shortened G 1 phase (2, 5-7). The addition of mitogen can lead to the expression of one, two, and sometimes all three D-type cyclins during the G 1 phase, depending upon the mitogen and the cell type. For example, CSF-1 1 induces the expression of cyclin D1 and to a lesser extent D2 (but not D3) in macrophages (8, 9). D-type cyclins are essential cofactors for the kinases cdk4 and cdk6, and a key substrate for the cyclin D/cdk holoenzyme is the retinoblastoma protein (pRB) (see Ref.
Cyclins are expressed during mitogenesis and control eukaryotic cell proliferation. D-type cyclins are induced by mitogens and are considered to be growth factor sensors (1) . They are rate-limiting and essential for G 1 progression in normal mammalian cells since inhibition of either cyclin D1 (2, 3) or cyclin D2 (4) function will block G 1 progression in a number of cell types, whereas enforced expression of either cyclin can result in a shortened G 1 phase (2, (5) (6) (7) . The addition of mitogen can lead to the expression of one, two, and sometimes all three D-type cyclins during the G 1 phase, depending upon the mitogen and the cell type. For example, CSF-1 1 induces the expression of cyclin D1 and to a lesser extent D2 (but not D3) in macrophages (8, 9) . D-type cyclins are essential cofactors for the kinases cdk4 and cdk6, and a key substrate for the cyclin D/cdk holoenzyme is the retinoblastoma protein (pRB) (see Ref.
1 for review). Phosphorylation of pRB results in the release of its repression of specific transcription factors such as E2F, thereby allowing the transcription of a variety of genes required for proliferation (1) . The data showing similar expression patterns and functions of D-type cyclins have led to suggestions that they may act redundantly, although there are reports suggesting they may also have distinct roles (10 -12) .
Recently it was shown that cyclin D1 can bind to the estrogen receptor and enhance its transcriptional activity, independent of any cdk4 activation (13, 14) . These data suggest that following mitogenic stimuli cyclin D1 plays additional roles independent of activating cdks. Complementary to their integral role in controlling proliferation, D-type cyclins have also been shown to prevent cell differentiation. For example, enforced expression of cyclins D2 or D3 inhibits granulocyte-CSF-induced differentiation of myeloid cells (12) , whereas enforced expression of cyclin D1 blocks myogenic differentiation (15, 16) . These and other data have led to suggestions that cyclin D⅐cdk complexes may negatively influence the execution of differentiation programs (17) . LPS (bacterial lipopolysaccharide or endotoxin) is a potent macrophage-activating agent. The addition of LPS to macrophages results in a number of functional responses including release of nitric oxide and cytokines and priming for respiratory burst activity (see Ref. 18 for review). Previously we have reported that LPS potently inhibits CSF-1-stimulated macrophage proliferation (19) . Consistent with this anti-mitogenic action, LPS inhibited CSF-1-induced cyclin D1 and cdk4 expression and pRB phosphorylation (9, 20) . Given its inhibitory effect on CSF-1-induced cyclin D1 in macrophages, the present study examined the effect of LPS on expression of the other mitogen-induced D-type cyclin in macrophages, cyclin D2. We unexpectedly found that despite its anti-mitogenic effects, LPS enhanced CSF-1-stimulated cyclin D2 expression in primary cultures of normal mouse bone marrow-derived macrophages (BMM). Furthermore, the addition of LPS alone to quiescent BMM raised levels of cyclin D2 but not cyclin D1. By using specific kinase inhibitors we found that LPS induction of cyclin D2 was regulated by MAP kinase pathways. In addition, we found that elevation of intracellular cAMP did not induce cyclin D2 mRNA nor did it alter expression of LPS-induced cyclin D2 protein, showing that unlike cyclin D1, cyclin D2 in BMM does not appear to be regulated by cAMP-dependent protein kinase A pathways.
The data show that LPS can simultaneously elevate CSF-1-stimulated cyclin D2 while repressing CSF-1-stimulated cyclin D1, indicating inverse regulation of D-type cyclins. Importantly, the observation that LPS alone raises cyclin D2 demonstrates elevation of a D-type cyclin in the absence of proliferation. This implies that cyclin D2 has functions other than being a growth factor sensor and mediator of cell division and suggests it plays a role in macrophage activation by LPS.
EXPERIMENTAL PROCEDURES
Reagents-Reagents were obtained from the following sources: RPMI media from ICN-Flow Laboratories, Sydney, Australia; fetal calf serum from CSL Ltd., Parkville., Australia; L-cell conditioned medium was used as a source of CSF-1 and was prepared as described previously (21) ; recombinant human CSF-1 was a gift from Chiron; lipopolysaccharide (LPS) was purchased from Difco and prepared from Escherichia coli 0111:B4 by the Westphal method.
Antibodies-Anti-cyclin D2 antibodies were either (a) a rabbit polyclonal antibody that was raised against cyclin D2 and weakly crossreacts against cyclin D1, but not with cyclin D3, purchased from Santa Cruz Biotechnology Inc., catalog number sc-181 (immunizing peptide was purchased from the same source), or (b) rat monoclonal anti-cyclin D2 antibody 34B1-3, purchased from Santa Cruz (catalog number sc-452). Anti-phospho-erk1/2 (catalog number 9100) and anti-phosphop38 (catalog number 9211S) were purchased from New England Biolabs.
The SmithKline Beecham compound SB202190 was a gift from Amgen Biologicals and was prepared as a 5 mM stock in ethanol or Me 2 SO. PD98059 was purchased from New England Biolabs and was prepared as a 20 mM stock in Me 2 SO .
Full-length mouse cyclin D2 cDNA was a generous gift from Dr. Charles Sherr, St. Jude Children's Research Hospital, Memphis, TN (8) . Details of the murine cyclin D1 probe have been published previously (9) .
Cells-Primary cultures of normal mouse bone marrow-derived macrophages (BMM) were generated from CBA-C57Bl/6 mice, as described previously (21) , and were grown in RPMI, 10% fetal calf serum, 15% L-cell conditioned media, and 1500 units/ml rhCSF-1. Prior to experiments subconfluent BMM were synchronized in a quiescent state (G 0 /early G 1 ) by incubation for 18 h in the above media without growth factor (i.e. deficient in L-cell conditioned media and rhCSF-1).
Northern Blotting-Northern blotting was performed essentially as described previously (22) . Briefly, quiescent BMM in a 10-cm tissue culture dish (approximately 5 ϫ 10 6 cells) was treated as described in the text, and total RNA was isolated based upon the procedure of Chomczynski and Saachi (23) . RNA was electrophoresed on 1.2% agarose gels containing formaldehyde. Prior to overnight transfer to Hybond N ϩ membranes (Amersham Corp.), gels were incubated in 50 mM NaOH, 10 mM NaCl for 45 min at room temperature, and then neutralized in 0.1 M Tris⅐HCl, pH 7.5, for 45 min at room temperature. Membranes were incubated with 32 P-radiolabeled cDNA, washed, and exposed to Kodak XAR autoradiographic film at Ϫ70°C using intensifying screens. Membranes probed for cyclin D1 and cyclin D2 were exposed for 3-5 days and 1-2 weeks, respectively. The amount of RNA loaded in each lane was monitored by visualization of RNA in gels and on membranes by UV exposure following ethidium bromide staining and also by probing membranes for the expression of either of two "control" genes, ␤2-microglobulin (22) or 36B4 ribosomal phosphoprotein (24) .
Immunoprecipitation of 35 S-Labeled Proteins-Quiescent BMM in 10-cm dishes were stimulated with the agents described for 5 h and then washed gently in warm phosphate-buffered saline (PBS) and metabolically labeled by re-addition of agents in methionine/cysteine-free media (ICN-Flow, New South Wales, Australia) containing 1% fetal calf serum and 150 Ci of Tran 35 S-label (mix of 35 S-labeled L-Met (75%) and L-Cys (15%) purchased from ICN Pharmaceuticals Inc., Costa Mesa, CA) for a further 3 h in a final volume of 2.5 ml. Cells were gently washed (3 ϫ 5 ml PBS), and 0.7 ml of RIPA buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 0.2% SDS, 0.5% sodium deoxycholate, 0.5% Triton X-100) containing a protease/phosphatase inhibitor mixture (100 mM NaF, 200 M sodium orthovanadate, 70 IU of aprotinin, 10 g/ml leupeptin, 1 mM EDTA, 0.1 mM Pefablock (Calbiochem)) was added; cells were scraped and further disrupted by 3 passages through a 25-gauge needle, placed on ice for 15 min, and centrifuged for 20 min at 13,000 rpm in a microcentrifuge, and the supernatant was frozen at Ϫ80°C. Protein concentrations were determined using the method of Peterson (25), and immunoprecipitations were performed on 700 g of protein.
Lysates were pre-cleared by addition of 10 l of protein A-Sepharose (Pharmacia, Uppsala, Sweden) slurry and rotation for 30 min at 4°C. The supernatant was collected, and a second pre-clearing step was then performed using protein A-Sepharose beads that had been pretreated by incubation with non-immune rabbit serum. After pre-clearing, the samples were placed in a heat block at 95°C for 4 min, chilled on ice for 10 min, then centrifuged for 15 min at 13,000 rpm at 4°C. The supernatants were collected and antibody/antisera added at 1/150 dilution (final concentration of 0.67 g/ml polyclonal rabbit anti-cyclin D2 antibody). For control incubations containing cyclin D2 immunizing peptide, antibody was preincubated with 10-fold mass of peptide for 1 h at 37°C before addition to lysate. Immunoprecipitations were performed overnight at 4°C with rotation, after which 20 l of protein A-Sepharose slurry was added for 1 h at 4°C with rotation. Tubes were microcentrifuged, and the protein A-Sepharose pellet was washed (2 ϫ 1 ml RIPA buffer), 50 l of SDS-PAGE sample buffer added, tubes heated for 5 min at 95°C, and samples loaded onto 12% SDS-PAGE gels. Following electrophoresis gels were immersed in Amplify (Amersham Corp., UK) (10 min), dried, and exposed to Kodak XAR Safety Film for up to 7 days at Ϫ80°C, with intensifying screens. In experiments using antimouse cyclin D2 rat monoclonal antibody for immunoprecipitation a modification of this procedure was used. Briefly, the modification was lysis of cells in 1 ml of TNN buffer (50 mM Tris⅐HCl, pH 7.4, 120 mM NaCl, 5 mM EDTA, 0.5% Nonidet P-40, 50 mM NaF, 0.2 mM sodium orthovanadate, 1 mM dithiothreitol, 50 g/ml phenylmethylsulfonyl fluoride, 2 g/ml leupeptin, and 10 g/ml aprotinin). After 30 min rotation at 4°C the lysate was centrifuged at 10,000 ϫ g for 10 min at 4°C. Supernatants were precleared for 30 min with protein A-Sepharose (Pharmacia) and then incubated with 1 g/ml anti-mouse cyclin D2 rat monoclonal antibody (34B1-3) at 4°C with rotation for ϳ4 h. Secondary antibody (rabbit anti-rat IgG; Dako) was added for 30 min prior to the addition of 30 l of a 50% (w/v) slurry of protein A-Sepharose, and the incubation was continued for 30 min. Immune complexes were collected by centrifugation and washed four times with TNN buffer. Samples were resuspended in SDS sample buffer, boiled, and fractionated by SDS-PAGE in 4 -20% gradient gels (Novex) and visualized as described above.
RESULTS

LPS Enhances CSF-1-stimulated
Cyclin D2 ExpressionPreviously we have shown that LPS, a potent macrophage anti-mitogen (19) , inhibits the CSF-1-stimulated induction of cyclin D1 mRNA and protein in bone marrow-derived macrophages (BMM) (9, 20) . Since macrophages also express cyclin D2 in response to CSF-1 (8), we were interested in the effects of LPS on expression of this D-type cyclin. The Northern blot data presented in Fig. 1 show that addition of 5000 units/ml CSF-1 to quiescent BMM resulted in a relatively weak increase in the level of cyclin D2 mRNA which was maximal between 1 and 2 h and remained elevated for at least 8 h. The co-addition of 100 ng/ml LPS enhanced the CSF-1 induction of cyclin D2 from 2 h, reaching maximal levels around 4 -8 h. Levels of cyclin D2 mRNA remained elevated for at least 24 h (data not shown).
FIG. 1. LPS enhances CSF-1-stimulated cyclin D2 but inhibits CSF-1-stimulated cyclin D1 mRNA expression. Quiescent BMM (time 0) were stimulated with 5000 units/ml CSF-1 in the presence or absence of 100 ng/ml LPS for the indicated times. Total RNA was prepared for Northern blotting, and the same membrane was sequentially probed for cyclin D1 and cyclin D2. Membranes were also probed for ␤2-microglobulin expression to monitor RNA loading. These data are representative of three experiments. Fig. 1 also shows that when the same membrane was reprobed for cyclin D1, LPS was found to potently repress CSF-1-stimulated cyclin D1 mRNA levels, as previously reported (9) . Parallel DNA synthesis assays showed that the mitogenic response to CSF-1 was inhibited approximately 90% by LPS in these experiments and that LPS alone had no effect on DNA synthesis when added to quiescent BMM (data not shown), as reported previously (26) .
LPS Alone Induces Cyclin D2-We then investigated whether LPS alone could raise cyclin D2 mRNA levels. Quiescent BMM were incubated with either CSF-1, CSF-1 plus LPS, or LPS alone. The data in Fig. 2 show that addition of LPS alone to quiescent BMM raised cyclin D2 mRNA levels. This increase was greater than that induced by CSF-1 alone but usually slightly less than that induced by the combination of LPS and CSF-1. These data suggest that the increase in cyclin D2 mRNA levels following addition of CSF-1 plus LPS was mostly due to the effect of LPS and that LPS and CSF-1 act additively to induce cyclin D2.
By having observed the LPS-induced increases in cyclin D2 mRNA, we next determined whether these were reflected in levels of cyclin D2 protein. Since we were unable to consistently detect cyclin D2 using standard Western blotting procedures, we determined protein levels by immunoprecipitation of metabolically radiolabeled protein. Lysates prepared from radiolabeled cells were immunoprecipitated using a rabbit polyclonal anti-cyclin D2 antibody that weakly cross-reacts with cyclin D1 (see "Experimental Procedures"). Immunoprecipitated proteins were resolved by SDS-PAGE and visualized by autoradiography. The data in Fig. 3 show that two major bands were immunoprecipitated in the 32-36-kDa region from lysates prepared from CSF-1-stimulated cells (C). Two bands were anticipated given the antibody reacts with both cyclins D1 and D2 and that D1 migrates slightly slower than D2 (4, 27) . The various treatments modulated the lower cyclin D2 band as they did the cyclin D2 mRNA levels, in that CSF-1 slightly increased the levels over those observed in unstimulated cells (U), whereas the levels were greatly increased by either CSF-1 plus LPS (CL) or LPS alone (L). The modulations of the upper cyclin D1 band correlate with our previously published data (9, 20) showing LPS lowers levels of CSF-1-induced cyclin D1 mRNA and protein (see also Fig. 1 ). Neither band was observed when non-immune rabbit serum was used for immunoprecipitations nor following prior neutralization of the cyclin antibody with the immunizing peptide. These data indicate that the observed changes in cyclin D2 mRNA were reflected in protein levels and were confirmed in experiments using a monoclonal anti-cyclin D2 antibody (34B1-3) which did not appear to cross-react with cyclin D1 (Fig. 5B and data not shown) . Thus, LPS enhanced CSF-1-stimulated cyclin D2 protein expression but inhibited CSF-1-stimulated cyclin D1 protein levels. In addition, LPS alone (L) raised levels of cyclin D2 protein, but not cyclin D1, in quiescent BMM.
LPS Induction of Cyclin D2 Is Regulated by MAP Kinase Pathways-Mitogenic stimulation of D-type cyclin expression is regulated by MAP kinase family members in a number of cell types (28 -31) . Given that LPS is known to activate members of the MAP kinase family in macrophages (see Ref. 32 for review), and BMM in particular (33), we investigated whether these kinases regulated LPS-induced cyclin D2 expression. LPS was added to BMM in the presence or absence of either 100 M PD98059, which specifically blocks activation of MEK (34) (which is an activator of ERK), or 2.5 M SB202190, a specific inhibitor of p38 kinase activity (32) . The data in Fig. 4 show that PD98059 completely suppressed LPS-induced cyclin D2 mRNA (LP). The effect of PD98059 was concentration-dependent since 25 and 50 M PD98059 also significantly inhibited LPS-induced cyclin D2 mRNA, but 10 M usually had no effect (data not shown). By contrast, inhibition of p38 by SB202190 appeared to mildly but significantly and consistently enhance LPS-induced cyclin D2 mRNA levels (LS). The Me 2 SO vehicle alone had no effect on LPS-induced cyclin D2 (data not shown). Western blotting experiments using antibodies directed against phosphorylated forms of p44/42 ERKs or p38 showed, as expected, that addition of LPS to BMM resulted in phosphorylation of ERKs and p38 and that PD98059 inhibited this phosphorylation of the ERKs but not p38 (data not shown). That PD98059 had no effect on LPS-induced p38 phosphorylation indicated that the inhibition of LPS-induced cyclin D2 by PD98059 was not due to a nonspecific repression of BMM responsiveness to LPS.
Cyclin D2 Expression in BMM Is Not Regulated by cAMP-It was recently reported that activation of protein kinase A induced cyclin D2 mRNA in ovarian granulosa cells (35) . Since LPS addition to macrophages can elevate intracellular cAMP (36 -39), we investigated whether this might be a mechanism underlying LPS induction of cyclin D2. The addition of the membrane-permeable, non-metabolizable analogue of cAMP, 8-Br-cAMP (1 mM), had no effect on the level of cyclin D2 mRNA following 6 h of exposure (Fig. 5A) , despite having clear effects on cell morphology in these cultures (data not shown). We also examined the effect of 8-Br-cAMP on LPS-induced cyclin D2 since elevation of intracellular cAMP is known to block a number of macrophage LPS responses (Ref. 36 and also Ref. 40 for review), and elevation of intracellular cAMP inhibits CSF-1-induced proliferation (41) and cyclin D1 expression in macrophages (9, 20) . Quiescent BMM were either untreated (U), or incubated with 100 ng/ml LPS in the presence or absence of 1 mM 8-Br-cAMP for 6 h, with metabolic labeling occurring during the last 3 h (see "Experimental Procedures" for details). The data in Fig. 5B show that 8-Br-cAMP had no effect on LPS induction of cyclin D2 protein, despite having clear effects on the LPS-induced changes to morphology in these BMM cultures (data not shown).
DISCUSSION
Cyclins control proliferation of normal cells. Cyclin D2 is essential (4) and rate-limiting (2, 7) for proliferation in a number of mammalian cell types. The present study examined the effects of LPS on cyclin D2 expression in quiescent primary normal macrophages. LPS is a macrophage-activating agent FIG. 2 . LPS alone induces cyclin D2 mRNA expression. Quiescent BMM (time 0) were stimulated with 5000 units/ml CSF-1 (C), or 100 ng/ml LPS (L), or both (CL) for 6 h. Total RNA was prepared for Northern blotting, and the membrane was probed for cyclin D2. The membrane was also probed for ␤2-microglobulin expression to monitor RNA loading. Each lane comes from the same autoradiograph with irrelevant lanes excised for publication. These data are representative of nine experiments.
(see Ref. 18 for review) and potently inhibits macrophage proliferation (19, 20) . The current data show that LPS enhanced the expression of cyclin D2 induced by the mitogen CSF-1, while simultaneously repressing cyclin D1 expression. These data demonstrate not just differential regulation of the two D-type cyclins but diametrically opposed differential regulation. The present data also show LPS alone induced levels of cyclin D2 mRNA and de novo protein in quiescent BMM but did not induce cyclin D1 expression. Therefore, although cyclin D2 plays a conventional role as a growth factor sensor in macrophages (i.e. it is induced by CSF-1), its induction by the nonmitogenic macrophage activator LPS suggests cyclin D2 may have additional functions in macrophages.
Although macrophages express both cyclin D1 and cyclin D2, distinct roles for these proteins have not been established. The observations that both genes are activated by a mitogenic stimulus in macrophages (Ref. 8 and this report) and that both proteins appear to perform similar functions (see Introduction) have led to suggestions of functional redundancy. To some measure this must be true since, despite widespread tissue expression of D-type cyclins, mice with targeted deletions of cyclins D1 or D2 develop relatively normally (35, 42) . The present data showing LPS enhances cyclin D2 but represses cyclin D1 expression demonstrate a dramatic distinction in expression of D-type cyclins under the same conditions in the same cell type, suggesting non-redundant roles. Independent regulation of cyclin D1 and cyclin D2 gene expression in macrophages is also suggested by the observations that whereas elevation of cAMP potently inhibits cyclin D1 induction (9, 20) , it does not affect cyclin D2 induction (present data).
Cyclin D2 apparently has a special role during germ cell development since female cyclin D2 Ϫ/Ϫ mice were infertile due to impaired growth of somatic granulosa cells surrounding the oocytes, whereas the testis size and sperm count in male mice was approximately halved, although this did not affect fertility (35) . Additional studies showed that mitogenic stimulation of normal granulosa cells with follicle-stimulating hormone induced cyclin D2 (but not cyclin D1 or D3), indicating a role for cyclin D2 in proliferation of these cells. Follicle-stimulating hormone induction of cyclin D2 appeared linked to its ability to increase intracellular levels of cAMP, since elevation of cAMP levels by forskolin had a similar effect. Although the triggering of protein kinase A pathways is linked with mitogenesis in this cell type, but is anti-mitogenic in BMM (20, 41), we investigated whether BMM cyclin D2 was under similar control. Such experiments are additionally relevant given LPS can induce prostaglandin E2 synthesis in BMM, which subsequently increases intracellular cAMP (39) . Our experiments using 8-Br-cAMP alone show that cyclin D2 mRNA expression in BMM was not up-regulated by protein kinase A pathways, indicating that (a) unlike in granulosa cells, cyclin D2 in macrophages is not induced by cAMP, and (b) LPS induction of cyclin FIG. 3 . Differential effects of LPS on cyclin D1 and cyclin D2 protein expression. Quiescent BMM were either left unstimulated (U) and metabolically labeled with [
35 S]Met/Cys for 3 h or stimulated with 5000 units/ml CSF-1 (C), 100 ng/ml LPS (L), or a combination of both (CL) for 8 h, the final 3 h of which they underwent [
35 S]Met/Cys metabolic labeling. The polyclonal antibody used for immunoprecipitation was directed against cyclin D2 but also cross-reacted against cyclin D1 (see "Experimental Procedures"). Immunoprecipitated material was electrophoresed and the gel dried and exposed to autoradiographic film (see "Experimental Procedures"). Control immunoprecipitations used non-immune rabbit sera (NIRS) instead of anti-cyclin D2 or anti-cyclin D2 after it had been preincubated with the immunizing peptide (see "Experimental Procedures"). These data are representative of five experiments. were treated with 1 mM 8-Br-cAMP (cAMP) or 100 ng/ml LPS for 6 h. Total RNA was prepared for Northern blotting, and the membrane was probed for cyclin D2. The membrane was also probed for 36B4 expression to monitor RNA loading. These data are representative of four experiments. B, quiescent BMM were either untreated (US) or stimulated with 100 ng/ml LPS in the presence or absence of 1 mM 8-Br-cAMP for 6 h, the final 3 h of which they underwent metabolic labeling with [ 35 S]Met/Cys. Cyclin D2 immunoprecipitates (monoclonal antibody 34B1-3) were electrophoresed, and the gel was dried and exposed to autoradiographic film. These data are representative of two experiments.
D2 is a specific response to this compound and not a general response to anti-mitogens by BMM. Furthermore, unlike for CSF-1-induced cyclin D1 (9, 20) , the raising of intracellular cAMP levels had no effect on LPS-induced cyclin D2 (Fig. 5B) . These data once again demonstrate an absence of cyclin D2 regulation by protein kinase A in BMM and highlight the specificity of the pathways leading to LPS induction of cyclin D2, given that cAMP is known to block a number of macrophage responses to LPS (Refs. 36 and 40 for review).
The application of mitogens or stress to cells results in the activation of MAP kinase family members. These kinases then move into the nucleus and can regulate activity of specific transcription factors (see Ref. 43 for review). Investigations using a number of cell types and a range of mitogens have shown that MAP kinase family members can regulate cyclin D1 gene expression (28 -31) . Given that the addition of LPS to macrophages leads to the activation of MAP kinase family members (32), we investigated whether the non-mitogenic induction of D-type cyclins is also regulated by MAP kinases. The experiments using the specific inhibitor of MEK activation, PD98059 (34) , indicated that LPS induction of cyclin D2 was regulated by MEK/ERK activity. LPS is also known to activate another MAP kinase family member, p38, the activity of which is linked to stress and inflammation responses (32) . The present work using the p38-specific inhibitor SB202190 (32) indicated that p38 activation was not required for LPS induction of cyclin D2 and may even negatively regulate cyclin D2 mRNA expression. Imidazole-containing compounds such as SB202190 are known to inhibit LPS-induced tumor necrosis factor and interleukin-1 production by macrophages (32), suggesting these cytokines do not play a role in LPS induction of cyclin D2 in BMM.
The regulation of D-type cyclin expression by MAP kinase family members reported here is similar to that reported by Lavoie et al. (28) who examined the links between MAP kinases and cyclin D1 expression following mitogenic stimulation of a fibroblastic cell line. Their data indicated that ERK kinases positively regulated mitogen-stimulated cyclin D1 transcription, whereas p38 appeared to negatively regulate transcription. Thus, it appears that D-type cyclin expression can be positively regulated by ERK kinases and negatively regulated by p38 activity, regardless of whether the stimulus is mitogenic (28) or non-mitogenic/activating (present data).
We are currently investigating the function of LPS-induced cyclin D2 in macrophages. Although the combination of CSF-1 and LPS strongly induces cyclin D2 (this report), pRB remains in its underphosphorylated state under these conditions (20) . Given that cyclin D2 is known to bind hypophosphorylated pRB (44, 45) we investigated whether LPS-induced cyclin D2 was associated with pRB. We were unable to co-immunoprecipitate pRB and cyclin D2 from lysates of cells treated with LPS or CSF-1 plus LPS (data not shown), suggesting there is no strong interaction between LPS-induced cyclin D2 and pRB. We also tried to determine the cellular localization of the LPS-induced cyclin D2, since mitogen-stimulated D-type cyclins are detected in the nucleus (3, 4, 46, 47) . However, we were unable to detect either mitogen-or LPS-induced cyclin D2 protein by immunofluorescence confocal microscopy using either polyclonal or monoclonal antibodies, despite being able to readily detect cyclin D1 in the nucleus of CSF-1-stimulated BMM (data not shown). These results probably reflect differences in the relative levels of expression of these two proteins. In further ongoing investigations we are determining whether LPS-induced cyclin D2 is associated with any kinase activity. We do not expect to observe any cdk4 activity since we have previously shown that LPS inhibits cdk4 levels in BMM (20) , and under these conditions pRB remains underphosphorylated (20) . Whether or not LPS affects the activities of other cdks by the induction of a cdk inhibitor, as has been reported for a number of anti-mitogenic agents (48), remains to be determined.
Macrophages are dynamic cells with a wide variety of functions. They have established roles in many pathological and physiological processes including inflammation, atherosclerosis, arthritis, angiogenesis, wound healing, tissue remodeling, and immune function. Our data suggest that the role of cyclin D2 in macrophages may be very complex, given that it is expressed following either proliferative (CSF-1), anti-proliferative (CSF-1 plus LPS), or non-mitogenic activating (LPS alone) stimuli. LPS is a component of Gram-negative bacteria and can promote a number of responses from macrophages, including production of nitric oxide, superoxides, and cytokines. Although D-type cyclins have established roles in cell proliferation, the present data suggest cyclin D2 may play a role in macrophage activation, thus implying a novel proliferation-independent function for this D-type cyclin.
